Pharmaceutical Excipients Market is expected to reach US$ 17.60 Billion by 2034

Cellulose Segment Drives Pharmaceutical Excipients Market Growth

According to our new research study named "Pharmaceutical Excipients Market Forecast to 2034 – Global Analysis – by Type, Clinical Indication, Functionality, Application, End User, and Geography," the market was valued at US$ 10.03 billion in 2025 and is projected to reach US$ 17.60 billion by 2034; it is expected to register a CAGR of 6.5% during 2026–2034. The surging demand for generic medications and advanced formulations, increasing research and development efforts in novel excipients, and growing biopharmaceuticals and biosimilars drive the adoption of pharmaceutical excipients. Growing advancements in multifunctional and nanotechnology excipients, and integration of AI and 3D printing in excipient innovation are projected to drive pharmaceutical excipients market trends in the coming years. 

Pharmaceutical excipients are inactive substances used in drug formulations to aid manufacturing, stability, bioavailability, and patient acceptability. They act as fillers, binders, preservatives, coatings, disintegrants, or flavoring agents. The increasing drug production and rising demand for generic medicines are driving the global pharmaceutical excipients market growth. The growth of biologics and advancements in drug delivery technologies are driving growth in the pharmaceutical excipients market size. Expanding pharmaceutical manufacturing, aging populations, and higher prevalence of chronic diseases boost excipient demand for improved formulation stability, safety, and patient compliance worldwide, contributing to the rising pharmaceutical excipients market size. 

Pharmaceutical Excipients Market, by Region, 2025 (%)
 

Pharmaceutical Excipients Market Analysis Based on Segmental Evaluation:

Based on type, the pharmaceutical excipients market is segmented into bioresorbable polymers and lipids and liposome-based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant proteins polyols and cyclodextrins, inorganic chemicals, and other types. The cellulose segment held a significant pharmaceutical excipients market share in 2025. The segment is growing due to its versatility, safety, and wide functionality in drug formulations. Microcrystalline cellulose and hydroxypropyl methylcellulose, which are cellulose derivatives, function as binding agents, filling materials, disintegration components, and coating substances in tablet and capsule production. Manufacturers show a strong preference for these materials owing to their stable performance, safe nature, and ability to work well with active pharmaceutical ingredients (APIs). The market for solid oral dosage forms shows growth owing to increased demand, while generic drug production expands and pharmaceutical research and development activities increase. Cellulose excipients enable improved drug solubility, controlled release, and bioavailability, which scientists use to create more effective medicines that patients can easily use.

The geographical scope of the pharmaceutical excipients market report encompasses an assessment of the market performance in North America, Europe, Asia Pacific, South America, Central America, the Middle East, and Africa. North America dominated the pharmaceutical excipients market share in 2025. The growth of the market is driven by the advanced healthcare system of the region, its pharmaceutical research capabilities, and its regulatory framework.

The expanding pharmaceutical and biotechnology industry in the US and Canada serves as a key market driver because it develops new drug formulations that need specialized excipients to enhance stability, bioavailability, and patient compliance. The rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer has increased the demand for effective medications, which increases the requirement for high-quality excipients. The rising use of generic drugs and biosimilars after patent expirations has created larger production volumes, which result in increased excipient usage. Drug delivery systems require technological advancements, which will enable the development of functional excipients that deliver better performance through controlled-release tablets, orally disintegrating tablets, and biologics, boosting the pharmaceutical excipients market growth.

Supportive regulatory frameworks from agencies such as the US Food and Drug Administration encourage innovation while maintaining safety standards, which strengthen the market. The region achieves market growth through its major pharmaceutical companies and excipient manufacturers who make substantial research and development investments. The industry experiences growth through three main factors, which include the rising adoption of multifunctional excipients, the expansion of contract manufacturing organizations, and the increasing emphasis on developing patient-centered drug formulations.
Recent developments highlight the US Food and Drug Administration's (FDA) emphasis on supply chain integrity; in February 2026, the agency issued guidance urging compounders to rigorously verify bulk drug substances and excipient suppliers to mitigate contamination risks. The FDA established the PreCheck program in August 2025, which created a system that allows faster inspections and approvals for excipient producers to enhance domestic pharmaceutical manufacturing capabilities. The FDA authorized 50 drugs in 2024, which included advanced excipients that used novel polymers for controlled release and lipid-based carriers to enhance solubility in diabetes and cardiovascular medications. The February 2024 update to the Handbook of Pharmaceutical Excipients introduced one new monograph and made changes to 17 existing monographs, which demonstrate consistent international standards for safety and effectiveness. 

The Cosmetic Ingredient Hotlist received updates in May 2024, which established new rules for pharmaceutical excipients owing to their restrictions on certain substances while promoting the use of safer multifunctional ingredients. The 2024 IMCD Canadian Pharmaceutical Summit featured discussions on innovative excipients from partners such as DFE Pharma, which focused on sustainable binders for solid dosage forms used in heart disease treatments. Health Canada's April 2024 additions to the Prescription Drug List included therapies relying on advanced excipients for better bioavailability in diabetes care. These advancements align with current Good Manufacturing Practice (cGMP) regulations, ensuring excipients meet stringent purity and functionality requirements. 

JRS PHARMA GmbH & Co KG, Roquette Freres SA, BASF SE, Evonik Industries AG, Ashland Inc, Archer-Daniels-Midland Co, The Dow Chemical Co, The Lubrizol Corp, Avantor Inc, MEGGLE GmbH & Co KG, and Merck KGaA are among the leading companies profiled in the pharmaceutical excipients market report.

Based on type, the pharmaceutical excipients market is divided into bioresorbable polymers and lipids and liposome based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant proteins polyols and cyclodextrins, inorganic chemicals, and other types. In terms of clinical indication, the market is segmented into cancer, metabolic, infectious disease, dental, ophthalmic, cardiovascular, and other clinical indications. Based on functionality, the pharmaceutical excipients market is categorized into coloring agents and coating agents, sweetner and flavoring agents, suspending and viscosity agents, preservative and controlled release, antioxidant and oil, tablet filler and diluent, binder and compression and granulating agents, emulsifiers, surfactants, and other functionality. By application, the pharmaceutical excipients market is segmented into oral, injectable, topical, and other application. By end user, the market is classified into pharma industries, biopharma industries, animal health, and other end user. Geographically, the pharmaceutical excipients market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).